--- title: "Pulmatrix (PULM) news: reverse split and merger" url: "https://aibio.space/companies/pulmatrix/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "PULM reverse split and merger news: Pulmatrix stockholders approve Eos SENOLYTIX merger and a reverse split. Pulmatrix, Inc. (NASDAQ: PULM), United States." --- PULM Pulmatrix, Inc. NASDAQ · United States # Pulmatrix (PULM) news PULM reverse split and merger news Listings · 2026-10-27 ## [Pulmatrix stockholders approve Eos SENOLYTIX merger and a reverse split](https://aibio.space/news/pulmatrix-stockholders-approve-eos-senolytix-merger-reverse-split/) Pulmatrix stockholders approved all nine proposals on October 26, 2026, including a share issue above 20% to Eos holders, certain noteholders and adviser Palladium, and a reverse split of one new share for every 2 to 10. The 8-K says Eos and Pulmatrix holders could end up owning more or less of the combined company if the exchange ratio is adjusted. ## Latest Pulmatrix news 1. 2026-10-13 Mergers [Pulmatrix stockholders to vote October 26, 2026 on Eos SENOLYTIX merger](https://aibio.space/news/pulmatrix-stockholders-vote-october-26-2026-eos-senolytix-merger/) Pulmatrix stockholders are due to vote October 26, 2026 on a merger with Eos SENOLYTIX, Inc., whose lead data so far are mouse studies. The filing gives no amount for the merger-associated financings it expects, and the company's cash was $2.2 million at June 30, 2026. 2. 2025-05-15 Mergers [Pulmatrix says Cullgen merger registration is effective, plans to divest assets](https://aibio.space/news/pulmatrix-says-cullgen-merger-registration-effective-plans-divest/) Pulmatrix said the SEC declared effective the registration statement for its proposed merger with Cullgen, which it expects to close in June 2025. It plans to divest PUR3100 and its other assets as part of the deal. Its cash was $7.7 million on March 31, 2025. 3. 2025-05-15 Mergers [Pulmatrix says Cullgen merger filing is effective, expects June 2025 close](https://aibio.space/news/pulmatrix-says-cullgen-merger-filing-effective-expects-june-2025-close/) Pulmatrix says the SEC has declared effective its Form S-4 for the Cullgen merger, and expects a June 2025 close while it seeks buyers for its own assets. It had $7.7 million of cash at March 31, 2025, which it says lasts through the anticipated closing. 4. 2025-04-10 Mergers [Pulmatrix and Cullgen amend merger agreement, switching to a one-step merger](https://aibio.space/news/pulmatrix-cullgen-amend-merger-agreement-switching-one-step-merger/) Amendment No. 1, dated April 7, 2025, drops the second merger so Cullgen survives the merger as a wholly owned Pulmatrix subsidiary. It also clarifies the fractional shares provision. 5. 2025-04-10 Mergers [Pulmatrix amends Cullgen merger agreement to a one-step merger](https://aibio.space/news/pulmatrix-amends-cullgen-merger-agreement-one-step-merger/) Pulmatrix and Cullgen signed Amendment No. 1 to their merger agreement on April 7, 2025, dropping the planned second merger. The 8-K gives no exchange ratio, share count or valuation, and does not say why the structure changed. ## Pulmatrix at a glance - **Ticker**: PULM - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $2.2 million ### Related companies - [Matinas Biopharma Holdings](https://aibio.space/companies/matinas-biopharma/) AMEX: MTNB - [Windtree Therapeutics](https://aibio.space/companies/windtree-therapeutics/) OTC: WINT - [Parabilis Medicines](https://aibio.space/companies/parabilis-medicines/) NASDAQ: PBLS - [Liminatus Pharma](https://aibio.space/companies/liminatus-pharma/) NASDAQ: LIMN - [Vicapsys Life Sciences](https://aibio.space/companies/vicapsys-life-sciences/) OTC: VICP - [Tonix Pharmaceuticals Holding](https://aibio.space/companies/tonix-pharmaceuticals/) NASDAQ: TNXP - [Cellectar Biosciences](https://aibio.space/companies/cellectar-biosciences/) NASDAQ: CLRB - [Liquidia](https://aibio.space/companies/liquidia/) NASDAQ: LQDA ### Also on NASDAQ - [Propanc Biopharma](https://aibio.space/companies/propanc-biopharma/) PPCB - [Axogen](https://aibio.space/companies/axogen/) AXGN - [SANUWAVE Health](https://aibio.space/companies/sanuwave-health/) SNWV - [Nexalin Technology](https://aibio.space/companies/nexalin-technology/) NXL - [Erasca](https://aibio.space/companies/erasca/) ERAS - [Bionano Genomics](https://aibio.space/companies/bionano-genomics/) BNGO ## Pulmatrix annual financials | Line | FY2025 | FY2024 | |---|---|---| | Research and development | [$38,000](https://www.sec.gov/Archives/edgar/data/1574235/000149315226028902/) | [$7.2 million](https://www.sec.gov/Archives/edgar/data/1574235/000149315226028902/) | | Net income (loss) | [-$5.2 million](https://www.sec.gov/Archives/edgar/data/1574235/000149315226028902/) | [-$9.6 million](https://www.sec.gov/Archives/edgar/data/1574235/000149315226028902/) | | Cash from operations | [-$5.4 million](https://www.sec.gov/Archives/edgar/data/1574235/000149315226028902/) | [-$10.7 million](https://www.sec.gov/Archives/edgar/data/1574235/000149315226028902/) | | Cash and equivalents | [$4.1 million](https://www.sec.gov/Archives/edgar/data/1574235/000149315226037594/) | [$9.5 million](https://www.sec.gov/Archives/edgar/data/1574235/000149315226028902/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $2.2 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Pulmatrix Did Pulmatrix do a reverse stock split? Our latest story on this, dated Oct 27, 2026: "Pulmatrix stockholders approve Eos SENOLYTIX merger and a reverse split". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/pulmatrix-stockholders-approve-eos-senolytix-merger-reverse-split/). Is Pulmatrix involved in a merger or acquisition? Our latest story on this, dated Oct 27, 2026: "Pulmatrix stockholders approve Eos SENOLYTIX merger and a reverse split". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/pulmatrix-stockholders-approve-eos-senolytix-merger-reverse-split/). What is the ticker symbol of Pulmatrix? Pulmatrix, Inc. trades under the ticker PULM on NASDAQ. Where is Pulmatrix listed? Pulmatrix, Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:2PU. What is the SEC CIK of Pulmatrix? The SEC Central Index Key (CIK) for Pulmatrix, Inc. is 1574235. Its filings are on SEC EDGAR. How many shares does Pulmatrix have outstanding? 3,652,285 shares as of 2026-08-13, per the cover page of its 10-Q filed 2026-08-13. Which country or territory is Pulmatrix listed under? Our directory records Pulmatrix, Inc. under United States. What does Pulmatrix do? Our directory classifies Pulmatrix, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of Pulmatrix? The ISIN recorded for Pulmatrix, Inc. is US74584P3010. Does aibio.space cover Pulmatrix? aibio.space lists Pulmatrix, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Pulmatrix incorporated? SEC records list its state or country of incorporation as DE. Is Pulmatrix profitable? Pulmatrix, Inc. reported a net loss of $5.2 million for the fiscal year ended Dec 31, 2025, and used $5.4 million of cash in operations, per its annual report to the SEC. How much does Pulmatrix spend on research and development? $38,000 in the fiscal year ended Dec 31, 2025, per its annual report. How much cash does Pulmatrix have? $2.2 million in cash at Jun 30, 2026, per its 10-Q. What is the latest Pulmatrix (PULM) stock news? Our latest story on Pulmatrix, dated Oct 27, 2026: "Pulmatrix stockholders approve Eos SENOLYTIX merger and a reverse split". Pulmatrix stockholders approved all nine proposals on October 26, 2026, including a share issue above 20% to Eos holders, certain noteholders and adviser Palladium, and a reverse split of one new share for every 2 to 10. The 8-K says Eos and Pulmatrix holders could end up owning more or less of the combined company if the exchange ratio is adjusted. [Source](https://aibio.space/news/pulmatrix-stockholders-approve-eos-senolytix-merger-reverse-split/). ## Investor discussion: Pulmatrix Members talk about Pulmatrix (PULM). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Pulmatrix, newest first. Each line links the filing it comes from. 1. 2026-10-27 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). [Source](https://www.sec.gov/Archives/edgar/data/1574235/000149315226048644/form8-k.htm) 2. 2026-10-13 Mergers Filed documents for a merger or acquisition. SEC Form 425. [Source](https://www.sec.gov/Archives/edgar/data/1574235/000149315226046691/form425.htm) 3. 2026-09-22 Mergers Filed documents for a merger or acquisition. SEC Form 425. [Source](https://www.sec.gov/Archives/edgar/data/1574235/000149315226043709/form425.htm) 4. 2026-05-15 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/1574235/000149315226023368/form10-q.htm) 5. 2026-04-21 Mergers Reported a merger or acquisition agreement. SEC Form 8-K (Items 7.01,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1574235/000149315226018202/ex99-1.htm) 6. 2026-03-27 Listings Reported a reverse stock split. SEC Form 8-K (Items 1.01,3.02,3.03,5.01,5.03,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1574235/000149315226013266/ex99-1.htm) 7. 2026-03-02 Distress Reported the end of a material agreement. SEC Form 8-K (Items 1.02,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1574235/000149315226008449/ex99-1.htm) 8. 2025-12-18 Mergers Reported a merger or acquisition agreement. SEC Form 8-K (Items 7.01,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1574235/000149315225028283/ex99-1.htm) 9. 2025-06-16 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07,8.01). [Source](https://www.sec.gov/Archives/edgar/data/1574235/000164117225015249/form8-k.htm) 10. 2025-05-15 Mergers Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 2.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1574235/000164117225010525/ex99-1.htm) 11. 2025-04-10 Mergers Reported a merger or acquisition agreement. SEC Form 8-K (Items 1.01,5.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1574235/000164117225003620/form8-k.htm) 12. 2024-11-13 Mergers Reported a merger or acquisition agreement. SEC Form 8-K (Items 1.01,5.01,5.02,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1574235/000149315224044986/ex99-1.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:PULM on TradingView](https://www.tradingview.com/symbols/NASDAQ-PULM/). ## SEC filings and registration - **SEC name**: Pulmatrix, Inc. - **CIK**: 1574235 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: PULM (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: 945 CONCORD STREET, FRAMINGHAM, MA, 01701 - **Phone**: (888) 355-4440 - **Shares outstanding**: 3,652,285 as of 2026-08-13 (10-Q filed 2026-08-13) - **Former names**: Ruthigen, Inc. ### Recent filings (8-K and 6-K are the company's own announcements) - [10-Q](https://www.sec.gov/Archives/edgar/data/1574235/000149315226037594/form10-q.htm) filed 2026-08-13 - [8-K](https://www.sec.gov/Archives/edgar/data/1574235/000149315226037592/form8-k.htm) filed 2026-08-13 - [S-3](https://www.sec.gov/Archives/edgar/data/1574235/000149315226027179/forms-3.htm) filed 2026-06-04 - [10-Q](https://www.sec.gov/Archives/edgar/data/1574235/000149315226023368/form10-q.htm) filed 2026-05-15 - [8-K](https://www.sec.gov/Archives/edgar/data/1574235/000149315226023367/form8-k.htm) filed 2026-05-15 - [8-K](https://www.sec.gov/Archives/edgar/data/1574235/000149315226018202/form8-k.htm) filed 2026-04-21 - [8-K](https://www.sec.gov/Archives/edgar/data/1574235/000149315226013266/form8-k.htm) filed 2026-03-27 - [8-K](https://www.sec.gov/Archives/edgar/data/1574235/000149315226008449/form8-k.htm) filed 2026-03-02 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001574235), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Pulmatrix, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker PULM, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Pulmatrix, Inc. - **Ticker**: PULM - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Pharmaceuticals: Major - **ISIN**: US74584P3010 - **Other listed symbols**: GETTEX:2PU - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-PULM/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/pulmatrix/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Pulmatrix (PULM) news: reverse split and merger", 2026-10-31, https://aibio.space/companies/pulmatrix/